Posts

iORGANBIO and Mitsui Chemicals team up on AI-driven cell and organoid manufacturing

on

FDA investigates tumor reports linked to Zolgensma

on

argenx to acquire Unnatural Products for up to $1.15 billion

on

Hims & Hers and Eli Lilly agree to offer branded weight-loss drugs

on

Novartis’s Lp(a) drug sharply lowered the biomarker but did not prevent cardiovascular events

on

J&J’s oral Icotyde shows promising PsA results, but higher dose misses statistical mark

on

Zura Bio drops HS program after Phase 2 trial miss

on

CRISPR reports encouraging early zugo-cel responses across autoimmune disease cohorts

on

Vir’s hepatitis D drug combination succeeds in first pivotal study

on

Network Bio and Duke team up to build AI disease models

on

Moderna raises growth outlook as vaccine sales and newer products gain momentum

on

Ziltivekimab lowered inflammation markers, but ZEUS found no cardiovascular-event benefit

on

Moderna’s COVID vaccine sales power a Q3 revenue beat

on